Home > Insider Trading > Filing (0000939767-19-000178)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
939767	Exelixis Inc.	EXEL	Services-Commercial Physical & Biological Research (8731)	043257395

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1213140	Gisela Schwab	C/O Exelixis, Inc. 1851 Harbor Bay Parkway Alameda CA 94502	Pres, Prod Dev & Med Aff & Cmo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-10-01	30,000	$5.51	354,331	No	4	M	Direct
Common Stock	Disposition	2019-10-01	30,000	$17.87	324,331	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option (right to buy)	Disposition	2019-10-01	30,000	$5.51	30,000	$5.51

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2015-07-20	2020-09-17	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	14,880	Indirect	By 401(k)

Footnotes

Includes 71,448 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2019.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $17.63 to $18.02. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of October 1, 2019.
The option, representing the right to purchase a total of 160,000 shares of Exelixis, Inc. common stock, became exercisable as to 50% of such stock option on July 20, 2015 upon the satisfaction of one of the two performance goals set by the Compensation Committee. On December 10, 2014, the Compensation Committee determined that the second performance goal for the option had not, and would not, be achieved, resulting in the Reporting Person forfeiting the remaining 50% of such stock option.